IRIS Accounts Production v25.4.12.37 07190611 Board of Directors 1.1.25 31.12.25 31.12.25 Medium entities the manufacture of medical equipment. true false true true false false false true false These accounts have been prepared in accordance with the provisions applicable to companies subject to the medium-sized companies regime. Ordinary 1.00000 Ordinary 1.00000 iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 07190611 2024-12-31 07190611 2025-12-31 07190611 2025-01-01 2025-12-31 07190611 2023-12-31 07190611 2024-01-01 2024-12-31 07190611 2024-12-31 07190611 ns14:PoundSterling 2025-01-01 2025-12-31 07190611 ns10:Director1 2025-01-01 2025-12-31 07190611 ns10:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 07190611 ns10:MediumEntities 2025-01-01 2025-12-31 07190611 ns10:Audited 2025-01-01 2025-12-31 07190611 ns10:Medium-sizedCompaniesRegimeForDirectorsReport 2025-01-01 2025-12-31 07190611 ns10:Medium-sizedCompaniesRegimeForAccounts 2025-01-01 2025-12-31 07190611 ns10:FullAccounts 2025-01-01 2025-12-31 07190611 1 2025-01-01 2025-12-31 07190611 ns10:OrdinaryShareClass1 2025-01-01 2025-12-31 07190611 ns10:Director2 2025-01-01 2025-12-31 07190611 ns10:Director3 2025-01-01 2025-12-31 07190611 ns5:CurrentFinancialInstruments 2025-12-31 07190611 ns5:CurrentFinancialInstruments 2024-12-31 07190611 ns5:ShareCapital 2025-12-31 07190611 ns5:ShareCapital 2024-12-31 07190611 ns5:RetainedEarningsAccumulatedLosses 2025-12-31 07190611 ns5:RetainedEarningsAccumulatedLosses 2024-12-31 07190611 ns5:ShareCapital 2023-12-31 07190611 ns5:RetainedEarningsAccumulatedLosses 2023-12-31 07190611 ns5:RetainedEarningsAccumulatedLosses 2024-01-01 2024-12-31 07190611 ns5:RetainedEarningsAccumulatedLosses 2025-01-01 2025-12-31 07190611 4 2025-01-01 2025-12-31 07190611 4 2024-01-01 2024-12-31 07190611 ns5:NetGoodwill 2025-01-01 2025-12-31 07190611 ns5:IntangibleAssetsOtherThanGoodwill 2025-01-01 2025-12-31 07190611 ns5:LeaseholdImprovements 2025-01-01 2025-12-31 07190611 ns5:PlantMachinery 2025-01-01 2025-12-31 07190611 ns5:FurnitureFittings 2025-01-01 2025-12-31 07190611 ns15:UnitedKingdom 2025-01-01 2025-12-31 07190611 ns15:UnitedKingdom 2024-01-01 2024-12-31 07190611 ns15:Europe 2025-01-01 2025-12-31 07190611 ns15:Europe 2024-01-01 2024-12-31 07190611 ns15:UnitedStates 2025-01-01 2025-12-31 07190611 ns15:UnitedStates 2024-01-01 2024-12-31 07190611 ns15:Asia 2025-01-01 2025-12-31 07190611 ns15:Asia 2024-01-01 2024-12-31 07190611 ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount 2025-01-01 2025-12-31 07190611 ns5:TotalGeographicSegmentsIncludingAnyUnallocatedAmount 2024-01-01 2024-12-31 07190611 ns5:OwnedAssets 2025-01-01 2025-12-31 07190611 ns5:OwnedAssets 2024-01-01 2024-12-31 07190611 5 2025-01-01 2025-12-31 07190611 5 2024-01-01 2024-12-31 07190611 ns5:NetGoodwill 2024-12-31 07190611 ns5:NetGoodwill 2025-12-31 07190611 ns5:NetGoodwill 2024-12-31 07190611 ns5:LeaseholdImprovements 2024-12-31 07190611 ns5:PlantMachinery 2024-12-31 07190611 ns5:FurnitureFittings 2024-12-31 07190611 ns5:LeaseholdImprovements 2025-12-31 07190611 ns5:PlantMachinery 2025-12-31 07190611 ns5:FurnitureFittings 2025-12-31 07190611 ns5:LeaseholdImprovements 2024-12-31 07190611 ns5:PlantMachinery 2024-12-31 07190611 ns5:FurnitureFittings 2024-12-31 07190611 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-12-31 07190611 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-12-31 07190611 ns5:WithinOneYear 2025-12-31 07190611 ns5:WithinOneYear 2024-12-31 07190611 ns5:BetweenOneFiveYears 2025-12-31 07190611 ns5:BetweenOneFiveYears 2024-12-31 07190611 ns5:AllPeriods 2025-12-31 07190611 ns5:AllPeriods 2024-12-31 07190611 ns5:DeferredTaxation 2024-12-31 07190611 ns5:DeferredTaxation 2025-01-01 2025-12-31 07190611 ns5:DeferredTaxation 2025-12-31 07190611 ns10:OrdinaryShareClass1 2025-12-31

REGISTERED NUMBER: 07190611

BREAS MEDICAL LIMITED

STRATEGIC REPORT, REPORT OF THE DIRECTORS AND

FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2025

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

CONTENTS OF THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

Page |

| Strategic Report | 1 |

| Report of the Directors | 2 |

| Report of the Independent Auditors | 4 |

| Profit and Loss Account | 8 |

| Other Comprehensive Income | 9 |

| Balance Sheet | 10 |

| Statement of Changes in Equity | 11 |

| Cash Flow Statement | 12 |

| Notes to the Financial Statements | 13 |

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

STRATEGIC REPORT

FOR THE YEAR ENDED 31 DECEMBER 2025

The directors present their strategic report for the year ended 31 December 2025.

REVIEW OF BUSINESS

The company is a manufacturer of medical equipment of airway clearance devices. We continuously strive to improve the quality of life of patients worldwide, through the design and manufacturing of innovative and high-quality respiratory and sleep products.

With 48 employees and a sustained market leading presence within the UK, as well as export to more than 20 countries, the company has developed devices for the treatment and management of neuromuscular disease, COPD and other chronic conditions for more than 25 years.

The company's current market share position in the UK remains at approximately 70% within the Life support sector, 50% ventilation business and 80% within the MI-E (Mechanical Insufflation-Exsufflation) business. The company continues to face increasing competition within these markets.

PRINCIPAL RISKS AND UNCERTAINTIES

The current principal risks and uncertainties can be outlined as increasing competitor threat and number of entrants within the UK market and ongoing Government funding cuts to the NHS budget.

Financial instruments

The company did not use forward exchange contracts relating to foreign currency transactions and therefore all foreign currency risk is borne by the company.

There is no other material exposure of the company to risk relating to price, credit, liquidity or cash flow which in the opinion of the directors is material for the assessment of the assets, liabilities, financial position and profit of the company.

FUTURE DEVELOPMENTS

During 2026, the company will continue to grow EveryWare, a remote telemonitoring platform and prepare to launch a new iLink solution in this year. We will continue to expand our Education by Breas training platform, sharing knowledge and best practice in respiratory care. We also predict an increase in the core Clearway 2 business due to entry into new markets during 2026 such as the United States and Latin America. The Clearway 2 is rebranded Clearo for these new markets. In 2026 we also plan to launch patient interface, which should drive UK growth in a new segment area for Breas.

ON BEHALF OF THE BOARD:

J P Rowley - Director

17 March 2026

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

REPORT OF THE DIRECTORS

FOR THE YEAR ENDED 31 DECEMBER 2025

The directors present their report with the financial statements of the company for the year ended 31 December 2025.

DIVIDENDS

No dividends will be distributed for the year ended 31 December 2025.

DIRECTORS

The directors shown below have held office during the whole of the period from 1 January 2025 to the date of this report.

Y Liu

Ms C X Jin

J P Rowley

DISCLOSURE IN THE STRATEGIC REPORT

Information relating to financial instruments as required to be disclosed in the Report of the Directors is included in the Strategic Report in accordance with Companies Act s414C(11).

STATEMENT OF DIRECTORS' RESPONSIBILITIES

The directors are responsible for preparing the Strategic Report, the Report of the Directors and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law), including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- | select suitable accounting policies and then apply them consistently;

- | make judgements and accounting estimates that are reasonable and prudent;

- | prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITORS

So far as the directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the company's auditors are unaware, and each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's auditors are aware of that information.

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

REPORT OF THE DIRECTORS

FOR THE YEAR ENDED 31 DECEMBER 2025

AUDITORS

The auditors, H L Barnes, Statutory Auditors, will be proposed for re-appointment at the forthcoming Annual General Meeting.

ON BEHALF OF THE BOARD:

J P Rowley - Director

17 March 2026

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF

BREAS MEDICAL LIMITED

Opinion

We have audited the financial statements of Breas Medical Limited (the 'company') for the year ended 31 December 2025 which comprise the Profit and Loss Account, Other Comprehensive Income, Balance Sheet, Statement of Changes in Equity, Cash Flow Statement and Notes to the Financial Statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- | give a true and fair view of the state of the company's affairs as at 31 December 2025 and of its profit for the year then ended;

- | have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- | have been prepared in accordance with the requirements of the Companies Act 2006.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The directors are responsible for the other information. The other information comprises the information in the Strategic Report and the Report of the Directors, but does not include the financial statements and our Report of the Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF

BREAS MEDICAL LIMITED

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- | the information given in the Strategic Report and the Report of the Directors for the financial year for which the financial statements are prepared is consistent with the financial statements; and

- | the Strategic Report and the Report of the Directors have been prepared in accordance with applicable legal requirements.

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Report of the Directors.

We have nothing to report in respect of the following matters where the Companies Act 2006 requires us to report to you if, in our opinion:

- | adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or

- | the financial statements are not in agreement with the accounting records and returns; or

- | certain disclosures of directors' remuneration specified by law are not made; or

- | we have not received all the information and explanations we require for our audit.

Responsibilities of directors

As explained more fully in the Statement of Directors' Responsibilities set out on page two, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF

BREAS MEDICAL LIMITED

Auditors' responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

Discussion with the board and management involved in the risk and compliance functions of the company, including consideration of known or suspected instances of non-compliance with laws and regulation and fraud. Evaluation and testing of the board and senior management's controls, designed to prevent and detect irregularities. Assessment of management's investigation into any such reported matters and enquiry of those responsible for investigating suspected or alleged fraudulent activity within the company.

Reviewing relevant correspondence between the board and management.

Designing audit procedures to incorporate unpredictability around the nature, timing, or extent of our testing. The audit procedures include, but are not limited to, identifying and testing journal entries based on risk criteria, identifying and testing transactions entered outside the normal course of the company's business.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

As part of an audit in accordance with ISAs (UK), we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- | Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- | Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.

- | Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.

REPORT OF THE INDEPENDENT AUDITORS TO THE MEMBERS OF

BREAS MEDICAL LIMITED

- | Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Report of the Auditors to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Report of the Auditors. However, future events or conditions may cause the company to cease to continue as a going concern.

- | Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in a Report of the Auditors and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Robert Bowen BA (Hons) FCA (Senior Statutory Auditor)

for and on behalf of H L Barnes, Statutory Auditors

Chartered Accountants

Barclays Bank Chambers

Stratford upon Avon

Warwickshire

CV37 6AH

17 March 2026

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

PROFIT AND LOSS ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2025

| 2025 |  | 2024

| Notes | £ | £ |

TURNOVER | 3 | 27,826,172 |  | 27,447,569 |  |

Cost of sales | 16,416,379 |  | 16,709,147 |  |

GROSS PROFIT | 11,409,793 |  | 10,738,422 |  |

Administrative expenses | 6,986,177 |  | 5,799,611 |  |

OPERATING PROFIT | 5 | 4,423,616 |  | 4,938,811 |  |

Interest receivable and similar income | 906,994 |  | 1,082,793 |  |

5,330,610 |  | 6,021,604 |  |

Interest payable and similar expenses | 6 | 7,440 |  | - |  |

PROFIT BEFORE TAXATION | 5,323,170 |  | 6,021,604 |  |

Tax on profit | 7 | 1,354,955 |  | 1,468,626 |  |

PROFIT FOR THE FINANCIAL YEAR | 3,968,215 |  | 4,552,978 |  |

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

OTHER COMPREHENSIVE INCOME

FOR THE YEAR ENDED 31 DECEMBER 2025

| 2025 |  | 2024

| Notes | £ | £ |

PROFIT FOR THE YEAR | 3,968,215 |  | 4,552,978 |  |

OTHER COMPREHENSIVE INCOME | - |  | - |  |

TOTAL COMPREHENSIVE INCOME FOR THE YEAR | 3,968,215 |  | 4,552,978 |  |

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

BALANCE SHEET

31 DECEMBER 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Intangible assets | 8 | - |  | - |  |

Tangible assets | 9 | 816,831 |  | 857,849 |  |

816,831 |  | 857,849 |  |

CURRENT ASSETS

Stocks | 10 | 3,357,089 |  | 4,372,746 |  |

Debtors | 11 | 32,231,410 |  | 26,856,216 |  |

Cash at bank | 880,726 |  | 838,181 |  |

36,469,225 |  | 32,067,143 |  |

CREDITORS

Amounts falling due within one year | 12 | 3,471,181 |  | 3,081,436 |  |

NET CURRENT ASSETS | 32,998,044 |  | 28,985,707 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 33,814,875 |  | 29,843,556 |  |

PROVISIONS FOR LIABILITIES | 14 | 142,644 |  | 139,540 |  |

NET ASSETS | 33,672,231 |  | 29,704,016 |  |

CAPITAL AND RESERVES

Called up share capital | 15 | 100 |  | 100 |  |

Retained earnings | 33,672,131 |  | 29,703,916 |  |

SHAREHOLDERS' FUNDS | 33,672,231 |  | 29,704,016 |  |

The financial statements were approved by the Board of Directors and authorised for issue on 17 March 2026 and were signed on its behalf by:

J P Rowley - Director

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

STATEMENT OF CHANGES IN EQUITY

FOR THE YEAR ENDED 31 DECEMBER 2025

| Called up |

| share |  | Retained |  | Total

| capital |  | earnings |  | equity

£ | £ | £ |

Balance at 1 January 2024 | 100 |  | 25,150,938 |  | 25,151,038 |  |

Changes in equity

Total comprehensive income | - |  | 4,552,978 |  | 4,552,978 |  |

Balance at 31 December 2024 | 100 |  | 29,703,916 |  | 29,704,016 |  |

Changes in equity

Total comprehensive income | - |  | 3,968,215 |  | 3,968,215 |  |

Balance at 31 December 2025 | 100 |  | 33,672,131 |  | 33,672,231 |  |

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

CASH FLOW STATEMENT

FOR THE YEAR ENDED 31 DECEMBER 2025

| 2025 |  | 2024

| Notes | £ | £ |

Cash flows from operating activities

Cash generated from operations | 17 | 1,876,504 |  | 1,952,294 |  |

Interest paid | (7,440 | ) | - |  |

Tax paid | (1,566,039 | ) | (1,320,001 | ) |

Taxation refund | - |  | 116,882 |  |

Net cash from operating activities | 303,025 |  | 749,175 |  |

Cash flows from investing activities

Purchase of tangible fixed assets | (261,812 | ) | (291,259 | ) |

Sale of tangible fixed assets | 2,782 |  | - |  |

Loan to group undertakings | (906,994 | ) | (1,094,434 | ) |

Interest received | 906,994 |  | 1,082,793 |  |

Group undertakings current account | (1,450 | ) | (1,200 | ) |

Net cash from investing activities | (260,480 | ) | (304,100 | ) |

Increase in cash and cash equivalents | 42,545 |  | 445,075 |  |

Cash and cash equivalents at beginning of year | 18 | 838,181 |  | 393,106 |  |

Cash and cash equivalents at end of year | 18 | 880,726 |  | 838,181 |  |

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2025

1. | STATUTORY INFORMATION

| Breas Medical Limited is a private company limited by shares. The company is registered in England under number 07190611 and the address of the registered office is Barclays Bank Chambers, Bridge Street, Stratford-upon-Avon, Warwickshire, CV37 6AH. The company's place of business is Unit A2, The Bridge Business Centre, Timothy's Bridge Road, Stratford-upon-Avon, Warwickshire, CV37 9HW.

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Related party exemption

| The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

| Turnover

| Turnover represents sales of goods and services invoiced to customers during the year, with services revenue being recognised as contractual activity progresses, excluding value added tax.

| Goodwill

| Goodwill, being the amount paid in connection with the acquisition of the goodwill of a business in 2012, is being amortised evenly over its estimated useful life of ten years.

| Intangible assets

| Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.

| Improvements to property | - | Over the period of the lease

| Plant and machinery | - | 50% on cost, 20% on cost and 20% on reducing balance

| Fixtures and fittings | - | 25% on reducing balance

| Stocks

| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

2. | ACCOUNTING POLICIES - continued

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Research and development

| Expenditure on research and development is written off in the year in which it is incurred.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Leasing commitments

| Rentals paid under operating leases are charged to the profit and loss account on a straight line basis over the period of the lease.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

3. | TURNOVER

| The turnover and profit before taxation are attributable to the one principal activity of the company.

| An analysis of turnover by geographical market is given below:

| 2025 |  | 2024

£ | £ |

| United Kingdom | 17,278,172 |  | 14,538,403 |  |

| Europe | 5,722,976 |  | 6,262,920 |  |

| United States of America | 1,125,382 |  | 448,580 |  |

| Asia | 3,238,770 |  | 5,586,095 |  |

| Australia | 416,744 |  | 509,678 |  |

| Middle East | 44,128 |  | 61,290 |  |

| Africa | - |  | 40,603 |  |

27,826,172 |  | 27,447,569 |  |

4. | EMPLOYEES AND DIRECTORS

| 2025 |  | 2024

£ | £ |

| Wages and salaries | 3,105,810 |  | 2,740,844 |  |

| Social security costs | 406,385 |  | 319,066 |  |

| Other pension costs | 138,981 |  | 129,741 |  |

3,651,176 |  | 3,189,651 |  |

| The average number of employees during the year was as follows:

| 2025 |  | 2024

| Directors | 1 |  | 1 |  |

| Management and office | 9 |  | 7 |  |

| Production | 24 |  | 21 |  |

| Selling | 14 |  | 15 |  |

48 |  | 44 |  |

| 2025 |  | 2024

£ | £ |

| Directors' remuneration | 135,509 |  | 229,915 |  |

| Directors' pension contributions to money purchase schemes | 8,590 |  | 13,866 |  |

| The number of directors to whom retirement benefits were accruing was as follows:

| Money purchase schemes | 1 |  | 1 |  |

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

5. | OPERATING PROFIT

| The operating profit is stated after charging:

| 2025 |  | 2024

£ | £ |

| Other operating leases | 123,585 |  | 118,055 |  |

| Depreciation - owned assets | 292,155 |  | 128,917 |  |

| Loss on disposal of fixed assets | 7,893 |  | 38,230 |  |

| Auditors' remuneration | 16,700 |  | 16,200 |  |

| Foreign exchange differences | 243,288 |  | 62,174 |  |

6. | INTEREST PAYABLE AND SIMILAR EXPENSES |

| 2025 |  | 2024

£ | £ |

| Other interest | 7,440 |  | - |  |

7. | TAXATION

| Analysis of the tax charge

| The tax charge on the profit for the year was as follows:

| 2025 |  | 2024

£ | £ |

| Current tax:

| UK corporation tax | 1,351,487 |  | 1,424,813 |  |

| Group Relief payment | 363 |  | 300 |  |

| Total current tax | 1,351,850 |  | 1,425,113 |  |

| Deferred tax | 3,105 |  | 43,513 |  |

| Tax on profit | 1,354,955 |  | 1,468,626 |  |

| Reconciliation of total tax charge included in profit and loss

| The tax assessed for the year is higher than the standard rate of corporation tax in the UK. The difference is explained below:

| 2025 |  | 2024

£ | £ |

| Profit before tax | 5,323,170 |  | 6,021,604 |  |

| Profit multiplied by the standard rate of corporation tax in the UK of 25% (2024 - 25%) | 1,330,793 |  | 1,505,401 |  |

| Effects of:

| Expenses not deductible for tax purposes | 24,162 |  | (36,775 | ) |

| Total tax charge | 1,354,955 |  | 1,468,626 |  |

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

8. | INTANGIBLE FIXED ASSETS

| Goodwill

£ |

| COST

| At 1 January 2025

| and 31 December 2025 | 4,000,000 |  |

| AMORTISATION

| At 1 January 2025

| and 31 December 2025 | 4,000,000 |  |

| NET BOOK VALUE

| At 31 December 2025 | - |  |

| At 31 December 2024 | - |  |

9. | TANGIBLE FIXED ASSETS

| Improvements |  | Fixtures |

| to |  | Plant and |  | and |

| property |  | machinery |  | fittings |  | Totals

£ | £ | £ | £ |

| COST

| At 1 January 2025 | 44,107 |  | 1,104,956 |  | 163,018 |  | 1,312,081 |  |

| Additions | 3,995 |  | 245,703 |  | 12,114 |  | 261,812 |  |

| Disposals | - |  | (63,152 | ) | (1,149 | ) | (64,301 | ) |

| At 31 December 2025 | 48,102 |  | 1,287,507 |  | 173,983 |  | 1,509,592 |  |

| DEPRECIATION

| At 1 January 2025 | 31,636 |  | 335,871 |  | 86,725 |  | 454,232 |  |

| Charge for year | 3,440 |  | 266,529 |  | 22,186 |  | 292,155 |  |

| Eliminated on disposal | - |  | (53,443 | ) | (183 | ) | (53,626 | ) |

| At 31 December 2025 | 35,076 |  | 548,957 |  | 108,728 |  | 692,761 |  |

| NET BOOK VALUE

| At 31 December 2025 | 13,026 |  | 738,550 |  | 65,255 |  | 816,831 |  |

| At 31 December 2024 | 12,471 |  | 769,085 |  | 76,293 |  | 857,849 |  |

10. | STOCKS

2025 | 2024 |

£ | £ |

| Stocks | 3,357,089 |  | 4,372,746 |  |

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

11. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 11,020,016 |  | 6,539,428 |  |

| Amounts owed by group undertakings | 20,964,612 |  | 20,057,618 |  |

| Other debtors | 9,750 |  | 9,750 |  |

| Tax | 109,738 |  | - |  |

| Prepayments and accrued income | 127,294 |  | 249,420 |  |

32,231,410 |  | 26,856,216 |  |

12. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade creditors | 1,381,023 |  | 1,364,718 |  |

| Amounts owed to group undertakings | 478,537 |  | 479,625 |  |

| Tax | - |  | 104,812 |  |

| Social security and other taxes | 425,437 |  | 317,782 |  |

| Other creditors | 14,834 |  | 13,809 |  |

| Accruals and deferred income | 1,006,086 |  | 715,711 |  |

| Warranty provision | 165,264 |  | 84,979 |  |

3,471,181 |  | 3,081,436 |  |

13. | LEASING AGREEMENTS

| Minimum lease payments under non-cancellable operating leases fall due as follows:

2025 | 2024 |

£ | £ |

| Within one year | 207,993 |  | 170,215 |  |

| Between one and five years | 134,210 |  | 120,905 |  |

342,203 |  | 291,120 |  |

14. | PROVISIONS FOR LIABILITIES

2025 | 2024 |

£ | £ |

| Deferred tax | 142,644 |  | 139,540 |  |

| Deferred |

| tax |

£ |

| Balance at 1 January 2025 | 139,540 |  |

| Provided during year | 3,104 |  |

| Balance at 31 December 2025 | 142,644 |  |

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

15. | CALLED UP SHARE CAPITAL

| Allotted, issued and fully paid:

| Number: | Class: | Nominal | 2025 | 2024 |

| value: | £ | £ |

| 100 | Ordinary | £1 | 100 |  | 100 |  |

16. | CONTROL

| The immediate parent company is Breas Technologies (UK) Limited.

| The immediate intermediate holding company is Breas Medical Holdings AB, a company incorporated in Sweden. Further intermediate holding companies are, Fosun Medical Holdings AB, a company incorporated in Sweden, and Fosun Industrial Co., Limited, a company incorporated in China. The ultimate holding company is Shanghai Fosun Pharmaceutical (Group) Co., Limited a company whose shares are listed on the Main Board of the Hong Kong Stock Exchange (stock code: 2196).

| The smallest and largest group in which the company's accounts are consolidated is that headed by Shanghai Fosun Pharmaceutical (Group) Co., Limited.

17. | RECONCILIATION OF PROFIT BEFORE TAXATION TO CASH GENERATED FROM OPERATIONS

| 2025 |  | 2024

£ | £ |

| Profit before taxation | 5,323,170 |  | 6,021,604 |  |

| Depreciation charges | 292,155 |  | 128,917 |  |

| Loss on disposal of fixed assets | 7,893 |  | 38,230 |  |

| Finance costs | 7,440 |  | - |  |

| Finance income | (906,994 | ) | (1,082,793 | ) |

4,723,664 |  | 5,105,958 |  |

| Decrease/(increase) in stocks | 1,015,657 |  | (1,100,013 | ) |

| Increase in trade and other debtors | (4,358,462 | ) | (1,404,088 | ) |

| Increase/(decrease) in trade and other creditors | 495,645 |  | (649,563 | ) |

| Cash generated from operations | 1,876,504 |  | 1,952,294 |  |

| BREAS MEDICAL LIMITED (REGISTERED NUMBER: 07190611) |

NOTES TO THE FINANCIAL STATEMENTS - continued

FOR THE YEAR ENDED 31 DECEMBER 2025

18. | CASH AND CASH EQUIVALENTS

| The amounts disclosed on the Cash Flow Statement in respect of cash and cash equivalents are in respect of these Balance Sheet amounts:

| Year ended 31 December 2025

| 31.12.25 |  | 1.1.25

£ | £ |

| Cash and cash equivalents | 880,726 |  | 838,181 |  |

| Year ended 31 December 2024

| 31.12.24 |  | 1.1.24

£ | £ |

| Cash and cash equivalents | 838,181 |  | 393,106 |  |

19. | ANALYSIS OF CHANGES IN NET FUNDS

| At 1.1.25 | Cash flow | At 31.12.25

£ | £ | £ |

| Net cash |

| Cash at bank | 838,181 |  | 42,545 |  | 880,726 |  |

838,181 |  | 42,545 |  | 880,726 |  |

| Total | 838,181 |  | 42,545 |  | 880,726 |  |